Analysis of the mechanism underlying prevention of muscle fatigue by eldecalcitol, a new vitamin D3 analogue

2015 Fiscal Year Final Research Report

• Project/Area Number: 25462284
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Orthopaedic surgery
• Research Institution: Akita University
• Principal Investigator: Miyakoshi Naohisa 秋田大学, 医学(系)研究科(研究院), 准教授 (90302273)
• Co-Investigator(Kenkyū-buntansha): HONGO Michio 秋田大学, 医学部, 講師 (50375250) ; KASUKAWA Yuji 秋田大学, 医学研究科, 講師 (60375285)
• Research Collaborator: SAKAI Sadaoki ; SHIRAISHI Ayako
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: 筋・神経病学

Outline of Final Research Achievements

Activated vitamin D3 analogues, such as alfacalcidol (ALF) and eldecalcitol (ELD), are used for the treatment of osteoporosis. In recent years, vitamin D3 has been considered effective for not only bones, but also skeletal muscles and reduced risk of falls. In this study, we administered ALF or ELD to glucocorticoid-treated osteoporotic rats for 2 or 4 weeks to evaluate their effects on bones and skeletal muscles. The bone mineral density (BMD) of the femur was measured. Muscle strength, fatigue, cross-sectional area (CSA), and gene expressions in the lower limb were also measured. After 2 weeks of ALF treatment, the BMD was increased. After 2 weeks of treatment with ELD, the BMD and muscle-related gene expressions were increased. After 4 weeks of treatment with ELD, the muscle strength, CSA, and BMD tended to be maintained.

Free Research Field

医歯薬学